IL85603A - Synergistic compositions of interleukin-2 and mismatched double- stranded rna - Google Patents

Synergistic compositions of interleukin-2 and mismatched double- stranded rna

Info

Publication number
IL85603A
IL85603A IL85603A IL8560388A IL85603A IL 85603 A IL85603 A IL 85603A IL 85603 A IL85603 A IL 85603A IL 8560388 A IL8560388 A IL 8560388A IL 85603 A IL85603 A IL 85603A
Authority
IL
Israel
Prior art keywords
lymphokines
interleukin
dsrna
human
stranded rna
Prior art date
Application number
IL85603A
Other languages
English (en)
Other versions
IL85603A0 (en
Original Assignee
Hem Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hem Res Inc filed Critical Hem Res Inc
Publication of IL85603A0 publication Critical patent/IL85603A0/xx
Publication of IL85603A publication Critical patent/IL85603A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IL85603A 1987-03-03 1988-03-01 Synergistic compositions of interleukin-2 and mismatched double- stranded rna IL85603A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2136887A 1987-03-03 1987-03-03

Publications (2)

Publication Number Publication Date
IL85603A0 IL85603A0 (en) 1988-08-31
IL85603A true IL85603A (en) 1993-05-13

Family

ID=21803798

Family Applications (1)

Application Number Title Priority Date Filing Date
IL85603A IL85603A (en) 1987-03-03 1988-03-01 Synergistic compositions of interleukin-2 and mismatched double- stranded rna

Country Status (19)

Country Link
EP (1) EP0281380B1 (xx)
JP (1) JPH0713024B2 (xx)
KR (1) KR960008009B1 (xx)
CN (1) CN1054509C (xx)
AT (1) ATE130760T1 (xx)
AU (2) AU1256588A (xx)
CA (1) CA1336810C (xx)
DE (1) DE3854726T2 (xx)
DK (1) DK113188A (xx)
ES (1) ES2082749T3 (xx)
FI (1) FI880961A (xx)
IE (1) IE75895B1 (xx)
IL (1) IL85603A (xx)
NO (1) NO880946L (xx)
NZ (1) NZ223720A (xx)
PH (1) PH24467A (xx)
PT (1) PT86879B (xx)
RU (1) RU1836103C (xx)
ZA (1) ZA881512B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA881639B (en) * 1987-03-23 1989-02-22 Hem Res Inc Treatment of human viral infection by dsrna combined with viral inhibitors
DK0405315T3 (da) * 1989-06-30 1995-09-25 American Cyanamid Co Anvendelse af et fagocyt-aktiverende stof: LPS eller IL-2 til fremstilling af et lægemiddel til behandling af Staphylococcus aureus-infektioner hos køer
FR2766715B1 (fr) * 1997-08-04 2001-02-16 Scras Produit comprenant au moins de l'arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique simultanee, separee ou etalee dans le temps, dans le traitement d'une maladie virale
FR2768344B1 (fr) * 1997-08-26 2001-02-16 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale
FR2768345B1 (fr) * 1997-09-17 2001-05-04 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale, notamment d'une hepatite virale
TW589189B (en) * 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
BRPI9908967B1 (pt) 1998-03-20 2017-05-30 Benitec Australia Ltd processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US20020132257A1 (en) 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
EP2116602A1 (en) 2008-05-07 2009-11-11 Institut Gustave Roussy Combination products for treating cancer
US20130195919A1 (en) 2010-03-05 2013-08-01 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
CN106794246B (zh) 2014-08-08 2021-10-15 OncoQuest制药有限公司 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
CA3213217A1 (en) 2021-04-28 2022-11-03 Raphael Darteil Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113162B1 (en) * 1982-09-16 1989-07-19 Hem Research, Inc. Anti-proliferative action of dsnras on tumor cells
CA1326450C (en) * 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)

Also Published As

Publication number Publication date
CN1054509C (zh) 2000-07-19
KR880010776A (ko) 1988-10-24
NO880946D0 (no) 1988-03-03
DE3854726D1 (de) 1996-01-11
DK113188D0 (da) 1988-03-02
EP0281380B1 (en) 1995-11-29
EP0281380A3 (en) 1989-09-27
PH24467A (en) 1990-07-18
CN1032296A (zh) 1989-04-12
IL85603A0 (en) 1988-08-31
PT86879B (pt) 1992-05-29
RU1836103C (ru) 1993-08-23
AU1256588A (en) 1988-09-01
PT86879A (pt) 1988-04-01
KR960008009B1 (ko) 1996-06-19
DE3854726T2 (de) 1996-07-25
FI880961A (fi) 1988-09-04
NZ223720A (en) 1991-07-26
EP0281380A2 (en) 1988-09-07
ES2082749T3 (es) 1996-04-01
CA1336810C (en) 1995-08-29
DK113188A (da) 1988-09-04
IE75895B1 (en) 1997-09-24
AU1618992A (en) 1992-08-06
ATE130760T1 (de) 1995-12-15
JPS63295514A (ja) 1988-12-01
IE880588L (en) 1988-09-03
ZA881512B (en) 1988-11-30
FI880961A0 (fi) 1988-03-02
NO880946L (no) 1988-09-05
JPH0713024B2 (ja) 1995-02-15

Similar Documents

Publication Publication Date Title
IL85603A (en) Synergistic compositions of interleukin-2 and mismatched double- stranded rna
NZ226005A (en) Covalent conjugates of a human cytokine and a human immunoglobulin, processes for their manufacture and pharmaceutical compositions thereof
DE3684305D1 (de) Antivirales immunotherapeutisches mittel und dessen herstellung.
MY104069A (en) Therapeutic nucleosides
IL78553A (en) Therapeutic compositions of phosphonylmethoxyalkyl adenines
OA08724A (fr) Treatment of human viral infections by dsRNA combined with viral inhibitors.
ES2099059T3 (es) Una composicion para promover el secuestro y extraccion del cuerpo de un animal de macromoleculas.
EP0296573A3 (en) Novel nucleosides, their preparation and pharmaceutical novel nucleosides, their preparation and pharmaceutical compositions compositions
HUT65404A (en) Protection from shock subsequent to injury by double-stranded rnas
EP0325018A3 (en) Rnase l inhibitor as a marker for virus infections
ES2016464A6 (es) Procedimiento para preparar derivados de 2', 5' -oligoadenilato.
DE69106877T2 (de) Aus blaualgen hergestellte biologisch aktive verbindungen.
ES2061496T3 (es) Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante.
MY111746A (en) Therapeutic nucleosides.
EP1013763A4 (en) INTERLEUKIN 18 AND INTERLEUKIN 18-CONVERTASE OF THE DOG, DNA MOLECULES CODING THEREOF, PROCESS FOR THE PRODUCTION OF INTERLEUKIN 18 AND MEANS FOR THE TREATMENT OF DISEASES OF THE IMMUNE SYSTEM IN DOGS.
DE3462891D1 (en) New pyrimidine derivatives endowed with antiviral activity
Kohl Additive effects of acyclovir and immune transfer in neonatal herpes simplex virus infection in mice
ES2007094A6 (es) Procedimiento para la preparacion de 3 -c- ciano-2,3 -didesoxinucleosido.
ES2072431T3 (es) D-acido aspartico beta-hidroxamato para el tratamiento de infecciones virales y de tumores.
CA2060490A1 (en) Protection from shock subsequent to injury by double-stranded rnas
Boonprakong Immune modulation with IL-2 and IL-12
MX9400210A (es) Tratamiento de infecciones virales.

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees